

dement: This form is estimeted to teke 0.03 hours to complete. Time will vary depending upon the needs of the individual case.
If the emount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent end Trademerk ion, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for

Washington, DC 20231

Practitioner's Docket No. MPI98-129M

PATENT

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

April 6, 2005

Simonne Corriveau

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Revocation of Prior Power of Attorney and Appointment of New

(2 pages) Power of Attorney (1 page) Change of Attorney Docket Number (1 page) Statement Under 37 CFR 3.73(b) Copy of Notice of Recordation of Assignment Document (1 page) Copy of Certificate of Ownership and Merger (3 pages) (1 page) "Fee Address" Indication Form

Total

Pages (10 pages) (Including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent end Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Practitioner's Docket No. MPI98-129M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LaRosa, Gregory J., et al

Application No.:

09/121,781

Patent No.:

6,312,689

Filed:

July 23, 1998

Issue Date:

November 6, 2001

For:

ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REVOCATION OF PRIOR POWERS OF ATTORNEY AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on <u>June 8, 2000</u>, at Reel <u>010907</u>, Frame <u>0917</u> hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10* I hereby certify that, on the date shown below, this correspondence is being: MAILING deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. 37 C.F.R. SECTION 1.10* 37 C.F.R. SECTION 1.8(a) as "Express Mail Post Office to Addressee" with sufficient postage as first class mail. Mailing Label No. TRANSMISSION transmitted by facsimile to the Patent and Trademark Office. 703-3 国 Simonne Corriveau April 6, 2005 (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MPI98-129M

Scott A. Brown	Reg. No. 32,724 Reg. No. 37,443		
Ian R. Silverman			
Jean M. Silveri	Reg. No. 39,030		
Janice M. Klunder	Reg. No. 41,121		
Karoline K.M. Shair	Reg. No. 44,332		
Kerri Pollard Schray	Reg. No. 47,066		
Tracy M. Sioussat	Reg. No. 50,609		

all of Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Group MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at 617-679-7336.

MILLENNIUM PHARMACEUTICALS, INC.

Typed Name

Jean M. Silveri

Title: Associate General Counsel

Dated: April 6, 2005

(Page 2 of 2)

Practitioner's Docket No. MPI98-129M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

T amplication of:	LaRosa, Gregory J., et al		
Application No.:	09/121,781	Patent No.:	6,312,689
Filed:	July 23, 1998	Issue Date:	November 6, 2001
For:	ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CHANGE OF ATTORNEY DOCKET NUMBER

Dear Sir:

Please note that the Attorney Docket Number has been changed to MPI98-129M. Please reference MPI98-129M on all future correspondence.

Respectfully submitted,

April 6, 2005

NIUM PHARMACEUTICALS, INC.

an M. Silveri

egistration No. 39,030

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10+

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"

Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Simonne Corriveau

Date: April 6, 2005

Ø

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)

PTO/SB/96 (09-04)
Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Tradamark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Tradamark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no parsons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Mlllennium Pharmaceuticals, Inc.		
Application No./Patent No.: 6,312,689 Filed/Issue Date: November 6, 200	01	
Entitled: ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR		
Millennium Pharmaceuticals. Inc. , a <u>a Delaware corporation</u> (Name of Assignee) (Type of Assignce, a.g., corporation, page 1)	artnership, university, government agency, atc.)	
states that it is: 1 the assignee of the entire right, title, and interest; or		
an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%		
in the patent application/patent identified above by virtue of either:		
A. An assignment from the inventor(s) of the patent application/patent identified about the United States Patent and Trademark Office at Reel 010907 Frame thereof is attached.	ove. The assignment was recorded 19917 or for which a copy	
OR B. A chain of title from the inventor(s), of the patent application/patent identified above below:		
From:	Office at	
The document was recorded in the United States Patent and Trademark on Reel, Frame, or for which a copy the	ereof is attached.	
From:		
_		
From:	Office at	
Reel, Frame, or for which a copy	y thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.		
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) Division in accordance with 37 CFR Part 3, if the assignment is to be recorded MPEP 302.08]	must be submitted to Assignment d in the records of the USPTO. <u>See</u>	
	eignee	
The undersigned (whose title is supplied below) is authorized to act on behalf of the as	ssignee. April 6, 2005	
Signature	Date	
	617-679-7336	
<u>Jean M. Silveri</u> Printed or Typed Name	Telephone Number	
Associate General Counsel	•	
Title		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or ratain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collaction is estimated to take 12 minutes to completa, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradamark Office, U.S. Depertment of Commerce, P.O. Box 1450, Alaxandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

AUGUST 31, 2000

PTAS

HAMILTON, BROOK, SMITH & REYNOLDS, P.C. HELEN E. WENDLER, ESQ. TWO MILITIA DRIVE LEXINGTON, MA 02421-4799



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 06/08/2000

REEL/FRAME: 010907/0917

NUMBER OF PAGES: 4

BRIEF: MERGER (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

LEUKOSITE, INC.

DOC DATE: 03/15/2000

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MASSACHUSETTS 02139


SERIAL NUMBER: 09121781

PATENT NUMBER:

FILING DATE: 07/23/1998

ISSUE DATE:

TONYA LEE, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS





State of Delaware Office of the Secretary of State

PAGE 1

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"LEUKOSITE, INC.", A DELAWARE CORPORATION,

WITH AND INTO "MILLENNIUM PHARMACEUTICALS, INC." UNDER THE NAME OF "MILLENNIUM PHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE SIXTEENTH DAY OF MARCH, A.D. 2000, AT 5:30 O'CLOCK P.M.



Edward J. Freel, Secre

2322355 B100M

001166184

AUTHENTICATION:

0354712

03-31-00

DATE: